fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Hydroxychloroquine sulfate

All products: general benefit

Plaquenil · DIN 02017709 · 200 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Savings card: RxHelp ONE lists PLAQUENIL (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Plaquenil · DIN 02017709 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Marketed since 2007-09-26 · brand PLAQUENIL · ATC P01BA02 HYDROXYCHLOROQUINE · form Tablet · route Oral · ingredients HYDROXYCHLOROQUINE SULFATE 200 MG · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $0.1576 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02017709)

Source record
DIN 02017709: Plaquenil Raw flags: sec3=Y Item: 082000002; group id 120; item number 0203; lccId None; manufacturer id SAV Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.6786; ministry $0.1576 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02017709 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14735
Interchangeable products
Apo-Hydroxyquine · DIN 02246691 · $0.1576 Hydroxychloroquine · DIN 02519348 · $0.1576 Jamp-Hydroxychloroquine · DIN 02491427 · $0.1576 Mint-Hydroxychloroquine · DIN 02424991 · $0.1576 NRA-Hydroxychloroquine · DIN 02511886 · $0.1576
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02017709
Shortage record checked October 6, 2026

Other products in the same Health Canada class (P01B): coverage varies; not interchangeable

  • Atovaquone + proguanil (Malarone): not a benefit
  • Mefloquine (Lariam): not a benefit
Other drugs in the same formulary class (08:20 Plasmodicides (Antimalarials)) and how they are covered

Matched class: 08:20 Plasmodicides (Antimalarials)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 08:20 Plasmodicides (Antimalarials)

ATOVAQUONE & PROGUANIL HCL

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 250mg & 100mg · Tab

MEFLOQUINE HCL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:20
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications PLAQUENIL (hydroxychloroquine sulfate tablets) is indicated for: • the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, in adult patients who have not responded satisfactorily to drugs with less potential for serious side effects. • the suppressive treatment and treatment of acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. PLAQUENIL is not active against the exo-erythrocytic forms of P. vivax, P. malariae and P. ovale, and therefore will neither prevent infection due to these organisms when given prophylactically, nor prevent relapse of infection due to these organisms. PLAQUENIL is highly effective as a suppressive agent in patients with vivax or malariae malaria in terminating acute attacks and significantly lengthening the interval between treatment and relapse. In patients with falciparum malaria, PLAQUENIL abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of P. falciparum (see 7 Warnings and Precautions, General, Malaria). 1.1. Pediatrics Pediatrics (< 18 y… https://pdf.hres.ca/dpd_pm/00083189.PDF PM date: 2026-01-16 Source product: PLAQUENIL; DIN 02017709; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Plaquenil · DIN 02017709 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02017709

Check this DIN again